BioVie Inc (NASDAQ:BIVI) announced Thursday that a data abstract from its Phase 2 open-label trial of its degenerative dementia drug candidate has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry.
The event will be held April 27-29 in San Diego, with BioVie’s presentation slated for April 28 at 5 pm PT.
The presentation is titled “Effects of NE3107 on Depression and Multimodal Outcomes in a Phase 2, Open-Label Study in Patients with Cognitive Decline Due to Degenerative Dementias.”
Earlier this week, the company also announced that data abstracts will be presented at the 2023 American Academy of Neurology Annual Meeting, being held virtually and in Boston, Massachusetts from April 22 to 27.
The company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB which lead to neuroinflammation and insulin resistance in neurodegenerative disease without impacting their homeostatic functions such as insulin signaling and neuron growth and survival, according to BioVie.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel